Regulatory news

2024-06-26

Redwood Pharma provides a new update regarding divestment of company assets

2024-05-23

Redwood Pharma provides an update on the company’s future

2023-11-30

Redwood Pharma AB (publ) changes Certified Adviser to Carnegie Investment Bank AB (publ)

2023-05-31

Redwood Pharma presents positive results from a clinical study with RP501 against dry eye

2022-12-15

Redwood Pharma enters partnership with Nextec medical in preparation for European market clearance of RP501

2022-05-10

Redwood Pharma AB (publ) Quarterly report January–March 2022

2022-03-28

Redwood Pharma receives approval from the Austrian drug authority to start RP501 clinical trial

2022-02-16

Redwood Pharma AB (publ) Year-end report 2021

2021-10-25

Accelerating development of RP501 first-line therapy for dry eye disease

2021-08-27

Redwood Pharma AB (publ) Quarterly report January–June 2021

2021-02-11

Redwood Pharma will receive approximately SEK 34.2 million through a heavily oversubscribed rights issue

2021-01-18

Redwood Pharma announces intention to move to Nasdaq First North Growth Market stock exchange

2020-09-08

Redwood Pharma launches new development program for mild dry eye based on its proprietary IntelliGel platform

2020-08-28

Quarterly Report January–June 2020

2020-07-23

New patent for the use of estrogens in the treatment of DED to be issued in the US

2020-06-18

Redwood Pharma secures bridge financing and issues warrants

2020-05-11

Quarterly report January – March 2020

2020-03-12

RP101 Phase II clinical results

2020-02-14

Redwood Pharma AB (publ) Year-end report 2019

2020-02-10

Patent to be granted in China regarding IntelliGel

2019-11-19

Redwood Pharma AB Quarterly Report January – September 2019

2019-11-12

Last patient completes treatment in RP101 Phase II clinical trial

2019-08-05

Last patient recruited in Redwood Pharma Phase II trial

2019-06-19

Update regarding financial situation

2019-06-18

Update regarding RP101 Phase II trial

2019-02-04

First patient treated in Redwood Pharma Phase II study

2019-01-07

Redwood Pharma receives its third and last national approval

2018-12-14

Redwood Pharma receives approval from another drug authority – the Austrian

2018-11-12

Redwood Pharma initiates clinical trial

2018-10-02

New patent for IntelliGel on the way in the EU

2018-08-29

Interim Report January – June 2018

2018-07-09

Redwood Pharma has submitted an application for the start of clinical trial

2018-04-26

Redwood Pharma’s new rights issue oversubscribed

2018-03-15

Redwood Pharma to execute New Rights Issue and takes important step in securing further financing

2018-03-08

Redwood Pharma acquires intellectual property rights

2018-02-26

Asian Pharmaceutical Firm to Evaluate IntelliGel®

2018-02-26

Positive meeting with Medical Products Agency prior to clinical Phase II trial

2018-02-23

Additional US patent to be granted regarding IntelliGel

2017-11-28

Redwood Pharma starts production of RP101 for clinical trials

2017-11-20

Toxicology and Safety Studies are Successfully Completed

2017-09-01

Redwood Pharma enters into agreement with CRO for clinical trial

2017-06-02

Redwood Pharma begins production of active ingredient in RP101 for Phase II studies

2017-03-15

Redwood Pharma initiates toxicological safety studies

2017-03-02

New US patent approved

2017-02-15

Redwood Pharma AB (publ) End of Year Report 2016

2017-02-13

Eye expert to support Redwood Pharma

2017-01-16

Redwood Pharma has developed a process for manufacture of the drug RP101 for coming safety studies

2016-02-23

Redwood Pharma raises SEK 6.6 million in private placement